BRIEF-Genmab says FDA lifts hold on zalutumumab studies

COPENHAGEN, July 16 (Reuters) - Danish biotechnology firm Genmab (GEN.CO) said on Thursday:

* The U.S. Food and Drug Administration lifted a partial clinical hold on zalutumumab studies being conducted under a U.S. Investigational New Drug application.

* "Enrolment of patients can now resume in the Phase II study in patients with head and neck cancer considered incurable with standard treatment and the Phase I/II frontline study of zalutumumab in combination with chemo-radiation."

(Reporting by Copenhagen newsroom)